November 20, 2024 Maria Dranishnikova Zacks raises target price for placenta-based drug maker BioStem
November 19, 2024 Maria Dranishnikova Zacks sees 600+% upside in vaping addiction drug maker Achieve Life Sciences
November 19, 2024 Maria Dranishnikova Liberty Energy shares gain as Trump taps founder for energy secretary
November 19, 2024 Vladislav Osipov Shares of small crypto exchange Bakkt surge 160% amid talks with Trump Media
November 18, 2024 Maria Dranishnikova Citius Pharmaceuticals plunges to all-time low after direct offering announced
November 18, 2024 Maria Dranishnikova Freedom spotlights small caps poised to rally on Trump second term
November 15, 2024 Maria Dranishnikova Hearing implant maker Envoy Medical rises on nine-month earnings
November 15, 2024 Maria Dranishnikova Surging TSS seen as alternative to Super Micro as new hot AI stock
November 14, 2024 Maria Dranishnikova Freedom Broker raises Viemed target price amid growing sleep therapy market
November 13, 2024 Maria Dranishnikova Sidus Space shares plummet after share offer with 45% discount announced
November 13, 2024 Maria Dranishnikova How the small IT services provider Innodata soared 3,000% over five years
November 13, 2024 Maria Dranishnikova Spirit Airlines shares plunge 60% after Frontier merger talks break down
November 12, 2024 Maria Dranishnikova Former unicorn 23andMe announces mass layoffs and closes research programs
November 12, 2024 Maria Dranishnikova Morgan Stanley: Postelection rally to continue, but without small caps
November 11, 2024 Maria Dranishnikova Freedom Broker spotlights Archer Aviation as small cap poised to rally on Trump win
November 8, 2024 Maria Dranishnikova Biotech company BioHarvest advances following Nasdaq listing approval
November 8, 2024 Maria Dranishnikova Innodata jumps over 30% on strong financials and Big Tech client news
November 7, 2024 Maria Dranishnikova Home medical services provider Viemed soars on third-quarter financials
November 6, 2024 Maria Dranishnikova Beauty-tech company Perfect Corp. seen as undervalued, with 70% upside